Table 2 Patient characteristics of studies proposed for inclusion in meta-analysis
From: Individual patient data meta-analysis of beta-blockers in heart failure: rationale and design
Trial (drug) by Year | n | Mean age | Male | Mean EF | Diabetes | On ACEi/ARB | Mean SBP (mmHg) | Mean HR (bpm) |
|---|---|---|---|---|---|---|---|---|
MDC (metoprolol) 1993 | 383 | 49 | 72% | 22% | n/s | 79% | 118 | 91 |
CIBIS (bisoprolol) 1994 | 641 | 60 | 83% | 25% | n/s | 90% | 126 | 83 |
US-HF (carvedilol) 1996 | 1,094 | 58 | 77% | 23% | 29% | 95% | 116 | 84 |
ANZ (carvedilol) 1997 | 415 | 67 | 80% | 29% | 19% | 85% | n/s | n/s |
CIBIS II (bisoprolol) 1999 | 2,647 | 61 | 80% | 28% | 12% | 96% | 130 | 80 |
MERIT-HF (metoprolol XL) 1999 | 3,991 | 64 | 78% | 28% | 25% | 96% | 130 | 83 |
COPERNICUS (carvedilol) 2001 | 2,289 | 63 | 80% | 20% | 26% | 97% | 123 | 83 |
CAPRICORN (carvedilol) 2001 | 1,959 | 63 | 74% | 33% | 22% | 98% | 121 | 77 |
BEST (bucindolol) 2001 | 2,708 | 60 | 78% | 23% | 36% | 98% | 117 | 82 |
CHRISTMAS (carvedilol) 2003 | (375)* | 63 | 90% | 29% | 22% | 87% | 126 | 78 |
SENIORS (nebivolol) 2005 | 2,128 | 76 | 63% | 36% | 26% | 89% | 139 | 79 |
TOTAL / WEIGHTED MEAN | 18,630 | 63 | 77% | 27% | 23% | 95% | 126 | 81 |